Clinical Trial Search

Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants

Primary: Overall Response Rate (ORR) — 45.16 percentage of participants

Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants

Primary: Change in Pain From Before Medication Administered (Baseline) to One-hour Post-baseline — 3.0; 3.0; 3.4; 3.1 Units on a scale — p=0.69

Primary: Median Overall Survival — 16; 20; 19 months — p=0.072

Primary: Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally) — -0.23; -0.99 score on a scale — p== 0.062

Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR

Primary: Overall Response Rate (ORR) — 53; 14; 35 Participants

Primary: Maximum Tolerated Dose of Everolimus for Participants With Recurrent Malignant Gliomas — 5 mg

Primary: Maximum Tolerated Dose of Bortezomib (Phase I) — 1.3 mg/m^2

Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants

Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants

Primary: Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain — 13; 3 Participants — p=0.006

Primary: Total Airway Volume (iVaw) — 49.033; 48.577; 51.101; 50.831 mL — p=0.727

Primary: Percentage of Participants With Grade II-IV Acute GVHD Between the 2 Groups — 12.2; 8.9 percentage of participants with aGVHD — p=0.508